Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 112

1.

Second-line therapy for gemcitabine-pretreated advanced or metastatic pancreatic cancer.

Altwegg R, Ychou M, Guillaumon V, Thezenas S, Senesse P, Flori N, Mazard T, Caillo L, Faure S, Samalin E, Assenat E.

World J Gastroenterol. 2012 Mar 28;18(12):1357-64. doi: 10.3748/wjg.v18.i12.1357.

PMID:
22493549
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Oral capecitabine in gemcitabine-pretreated patients with advanced pancreatic cancer.

Boeck S, Wilkowski R, Bruns CJ, Issels RD, Schulz C, Moosmann N, Laessig D, Haas M, Golf A, Heinemann V.

Oncology. 2007;73(3-4):221-7. doi: 10.1159/000127413. Epub 2008 Apr 17.

PMID:
18424886
[PubMed - indexed for MEDLINE]
3.

First-line erlotinib and fixed dose-rate gemcitabine for advanced pancreatic cancer.

Vaccaro V, Bria E, Sperduti I, Gelibter A, Moscetti L, Mansueto G, Ruggeri EM, Gamucci T, Cognetti F, Milella M.

World J Gastroenterol. 2013 Jul 28;19(28):4511-9. doi: 10.3748/wjg.v19.i28.4511.

PMID:
23901226
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

Second-line treatment with oxaliplatin, leucovorin and 5-fluorouracil in gemcitabine-pretreated advanced pancreatic cancer: A phase II study.

Tsavaris N, Kosmas C, Skopelitis H, Gouveris P, Kopterides P, Loukeris D, Sigala F, Zorbala-Sypsa A, Felekouras E, Papalambros E.

Invest New Drugs. 2005 Aug;23(4):369-75. Erratum in: Invest New Drugs. 2005 Dec;23(6):603. Kopteridis, Petros [corrected to Kopterides, Petros].

PMID:
16012797
[PubMed - indexed for MEDLINE]
5.

Irinotecan combined with gemcitabine, 5-fluorouracil, leucovorin, and cisplatin (G-FLIP) is an effective and noncrossresistant treatment for chemotherapy refractory metastatic pancreatic cancer.

Kozuch P, Grossbard ML, Barzdins A, Araneo M, Robin A, Frager D, Homel P, Marino J, DeGregorio P, Bruckner HW.

Oncologist. 2001;6(6):488-95.

PMID:
11743211
[PubMed - indexed for MEDLINE]
Free Article
6.

Prognostic factors and prognostic index for chemonaïve and gemcitabine-refractory patients with advanced pancreatic cancer.

Maréchal R, Demols A, Gay F, De Maertelaere V, Arvanitaki M, Hendlisz A, Van Laethem JL.

Oncology. 2007;73(1-2):41-51. doi: 10.1159/000120627. Epub 2008 Mar 11.

PMID:
18334830
[PubMed - indexed for MEDLINE]
7.

Docetaxel second-line therapy in patients with advanced pancreatic cancer: a retrospective study.

Saif MW, Syrigos K, Penney R, Kaley K.

Anticancer Res. 2010 Jul;30(7):2905-9.

PMID:
20683031
[PubMed - indexed for MEDLINE]
8.

A multicenter phase III trial comparing irinotecan-gemcitabine (IG) with gemcitabine (G) monotherapy as first-line treatment in patients with locally advanced or metastatic pancreatic cancer.

Stathopoulos GP, Syrigos K, Aravantinos G, Polyzos A, Papakotoulas P, Fountzilas G, Potamianou A, Ziras N, Boukovinas J, Varthalitis J, Androulakis N, Kotsakis A, Samonis G, Georgoulias V.

Br J Cancer. 2006 Sep 4;95(5):587-92. Epub 2006 Aug 8.

PMID:
16909140
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

Gemcitabine-based or capecitabine-based chemoradiotherapy for locally advanced pancreatic cancer (SCALOP): a multicentre, randomised, phase 2 trial.

Mukherjee S, Hurt CN, Bridgewater J, Falk S, Cummins S, Wasan H, Crosby T, Jephcott C, Roy R, Radhakrishna G, McDonald A, Ray R, Joseph G, Staffurth J, Abrams RA, Griffiths G, Maughan T.

Lancet Oncol. 2013 Apr;14(4):317-26. doi: 10.1016/S1470-2045(13)70021-4. Epub 2013 Mar 6.

PMID:
23474363
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

Stereotactic body radiotherapy and gemcitabine for locally advanced pancreatic cancer.

Mahadevan A, Jain S, Goldstein M, Miksad R, Pleskow D, Sawhney M, Brennan D, Callery M, Vollmer C.

Int J Radiat Oncol Biol Phys. 2010 Nov 1;78(3):735-42. doi: 10.1016/j.ijrobp.2009.08.046. Epub 2010 Feb 18.

PMID:
20171803
[PubMed - indexed for MEDLINE]
11.

A phase II study of S-1 in gemcitabine-refractory metastatic pancreatic cancer.

Morizane C, Okusaka T, Furuse J, Ishii H, Ueno H, Ikeda M, Nakachi K, Najima M, Ogura T, Suzuki E.

Cancer Chemother Pharmacol. 2009 Jan;63(2):313-9. doi: 10.1007/s00280-008-0741-7. Epub 2008 Apr 9.

PMID:
18398614
[PubMed - indexed for MEDLINE]
12.

Gemcitabine and ISIS-2503 for patients with locally advanced or metastatic pancreatic adenocarcinoma: a North Central Cancer Treatment Group phase II trial.

Alberts SR, Schroeder M, Erlichman C, Steen PD, Foster NR, Moore DF Jr, Rowland KM Jr, Nair S, Tschetter LK, Fitch TR.

J Clin Oncol. 2004 Dec 15;22(24):4944-50.

PMID:
15611509
[PubMed - indexed for MEDLINE]
13.

Overall survival of patients with advanced pancreatic cancer improved with an increase in second-line chemotherapy after gemcitabine-based therapy.

Zhang YD, Yang Q, Jiang ZM, Ma W, Zhou SW, Xie DR.

JOP. 2011 Mar 9;12(2):131-7.

PMID:
21386638
[PubMed - indexed for MEDLINE]
Free Article
14.

Phase II study of gemcitabine combined with uracil-tegafur in metastatic pancreatic cancer.

Lee J, Park JO, Kim WS, Lee SI, Song SY, Lim DH, Choi SH, Heo JS, Lee KT, Lee JK, Kim K, Jung CW, Im YH, Lee MH, Kang WK, Park K.

Oncology. 2004;66(1):32-7.

PMID:
15031596
[PubMed - indexed for MEDLINE]
15.

A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer.

Bramhall SR, Schulz J, Nemunaitis J, Brown PD, Baillet M, Buckels JA.

Br J Cancer. 2002 Jul 15;87(2):161-7.

PMID:
12107836
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

FOLFIRI regimen in metastatic pancreatic adenocarcinoma resistant to gemcitabine and platinum-salts.

Neuzillet C, Hentic O, Rousseau B, Rebours V, Bengrine-Lefèvre L, Bonnetain F, Lévy P, Raymond E, Ruszniewski P, Louvet C, Hammel P.

World J Gastroenterol. 2012 Sep 7;18(33):4533-41. doi: 10.3748/wjg.v18.i33.4533.

PMID:
22969226
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

Irinotecan plus raltitrexed vs raltitrexed alone in patients with gemcitabine-pretreated advanced pancreatic adenocarcinoma.

Ulrich-Pur H, Raderer M, Verena Kornek G, Schüll B, Schmid K, Haider K, Kwasny W, Depisch D, Schneeweiss B, Lang F, Scheithauer W.

Br J Cancer. 2003 Apr 22;88(8):1180-4.

PMID:
12698181
[PubMed - indexed for MEDLINE]
Free PMC Article
18.

Gemcitabine in elderly patients with advanced pancreatic cancer.

Hentic O, Dreyer C, Rebours V, Zappa M, Lévy P, Raymond E, Ruszniewski P, Hammel P.

World J Gastroenterol. 2011 Aug 14;17(30):3497-502. doi: 10.3748/wjg.v17.i30.3497.

PMID:
21941416
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

Phase II trial of gemcitabine and S-1 for patients with advanced pancreatic cancer.

Song H, Han B, Park CK, Kim JH, Jeon JY, Kim IG, Kim HJ, Jung JY, Kim JH, Kwon JH, Jang G, Kim HY, Kim HS, Choi DR, Zang DY.

Cancer Chemother Pharmacol. 2013 Oct;72(4):845-52. doi: 10.1007/s00280-013-2265-z. Epub 2013 Aug 27.

PMID:
23978987
[PubMed - indexed for MEDLINE]
20.

[Prognostic value of serum CA19-9 in patients with advanced pancreatic cancer receiving gemcitabine based chemotherapy].

An X, Li YH, Lin XB, Wang FH, Feng F, Xu RH, Jiang WQ, He YJ.

Ai Zheng. 2009 Mar;28(3):286-91.

PMID:
19619444
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk